SCHEMBL5535778

SCHEMBL5535778

FC(F)(F)Oc1ccc(OCC2CCC[N]2)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRIN2B Q13224 1/20 0.40
SCN10A Q9Y5Y9 1/20 0.38
MAOB P27338 2/20 0.38
KDM1A O60341 1/20 0.38
PTGER2 P43116 1/20 0.37
NISCH Q9Y2I1 1/20 0.37
PPARD Q03181 1/20 0.37
PPARA Q07869 1/20 0.37
DRD4 P21917 1/20 0.37
AOC3 Q16853 1/20 0.36
SLC6A4 P31645 2/20 0.36
GABBR2 O75899 1/20 0.36
GABBR1 Q9UBS5 1/20 0.36
ABL1 P00519 2/20 0.36
BCR P11274 2/20 0.36
EPHX1 P07099 1/20 0.35
EPHX2 P34913 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
LTA4H P09960 1/20 0.35
SLC6A3 Q01959 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5544897 0.84 PPARD (0.42) GRIN2BSCN10AMAOBNISCHPPARD
SCHEMBL5537079 0.83 PPARD (0.41) GRIN2BSCN10AMAOBNISCHPPARD
SCHEMBL5547966 0.82 PPARD (0.41) GRIN2BSCN10APPARDPPARAGABBR2
SCHEMBL5543396 0.82 PPARD (0.41) GRIN2BSCN10APPARDPPARAGABBR2
SCHEMBL4577525 0.81 LTA4H (0.55) MAOBPTGER2LTA4H
SCHEMBL4577709 0.81 LTA4H (0.55) MAOBPTGER2LTA4H
SCHEMBL5048690 0.81 LTA4H (0.55) MAOBPTGER2LTA4H
SCHEMBL5545285 0.80 TDP1 (0.47) DRD4
SCHEMBL5536178 0.79 TDP1 (0.46) LTA4H
SCHEMBL3163550 0.78 LTA4H (0.48) DRD4LTA4H

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP claimed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US claimed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US claimed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP claimed
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 GRIN2B 504/4885SCN10A 4013/4885MAOB 2140/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.